KR101606495B1 - 올리고뉴클레오타이드 킬레이트 복합체 - Google Patents

올리고뉴클레오타이드 킬레이트 복합체 Download PDF

Info

Publication number
KR101606495B1
KR101606495B1 KR1020137007008A KR20137007008A KR101606495B1 KR 101606495 B1 KR101606495 B1 KR 101606495B1 KR 1020137007008 A KR1020137007008 A KR 1020137007008A KR 20137007008 A KR20137007008 A KR 20137007008A KR 101606495 B1 KR101606495 B1 KR 101606495B1
Authority
KR
South Korea
Prior art keywords
rep
oligonucleotide
chelate complex
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137007008A
Other languages
English (en)
Korean (ko)
Other versions
KR20130099067A (ko
Inventor
앤드류 베일런트
미셀 바지넷
Original Assignee
레플리코르 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101606495(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레플리코르 인코포레이티드 filed Critical 레플리코르 인코포레이티드
Publication of KR20130099067A publication Critical patent/KR20130099067A/ko
Application granted granted Critical
Publication of KR101606495B1 publication Critical patent/KR101606495B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
KR1020137007008A 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체 Expired - Fee Related KR101606495B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
US61/375,257 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020157017340A Division KR20150082685A (ko) 2010-08-20 2011-08-18 올리고뉴클레오티드 킬레이트 복합체
KR20157007582A Division KR20150039873A (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체

Publications (2)

Publication Number Publication Date
KR20130099067A KR20130099067A (ko) 2013-09-05
KR101606495B1 true KR101606495B1 (ko) 2016-03-28

Family

ID=45594559

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137007008A Expired - Fee Related KR101606495B1 (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체
KR20157007582A Withdrawn KR20150039873A (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체
KR1020157017340A Withdrawn KR20150082685A (ko) 2010-08-20 2011-08-18 올리고뉴클레오티드 킬레이트 복합체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR20157007582A Withdrawn KR20150039873A (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체
KR1020157017340A Withdrawn KR20150082685A (ko) 2010-08-20 2011-08-18 올리고뉴클레오티드 킬레이트 복합체

Country Status (35)

Country Link
US (2) US8513211B2 (https=)
EP (1) EP2605794B1 (https=)
JP (1) JP5775581B2 (https=)
KR (3) KR101606495B1 (https=)
CN (2) CN103768086B (https=)
AU (1) AU2011291401B2 (https=)
BR (1) BR112013003875B1 (https=)
CA (2) CA2806616C (https=)
CL (1) CL2013000445A1 (https=)
CO (1) CO6670525A2 (https=)
CR (1) CR20130069A (https=)
CU (1) CU20130022A7 (https=)
CY (1) CY1118207T1 (https=)
DK (1) DK2605794T3 (https=)
DO (1) DOP2013000041A (https=)
EA (1) EA026660B1 (https=)
EC (1) ECSP13012449A (https=)
ES (1) ES2598556T3 (https=)
GT (1) GT201300040A (https=)
HR (1) HRP20161333T1 (https=)
HU (1) HUE029521T2 (https=)
IL (1) IL224237A (https=)
LT (1) LT2605794T (https=)
MX (1) MX340294B (https=)
MY (1) MY160961A (https=)
NZ (1) NZ606364A (https=)
PH (1) PH12013500192B1 (https=)
PL (1) PL2605794T3 (https=)
PT (1) PT2605794T (https=)
RS (1) RS55245B1 (https=)
SG (1) SG187165A1 (https=)
SI (1) SI2605794T1 (https=)
SM (1) SMT201600370B (https=)
WO (1) WO2012021985A1 (https=)
ZA (1) ZA201300497B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
CA2723672C (en) 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
SMT201700339T1 (it) 2012-04-23 2017-09-07 Biomarin Tech Bv Oligonucleotidi di modulazione dell'rna con caratteristiche migliorate per il trattamento dei disturbi neuromuscolari
EP3511022A1 (en) * 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
MY168778A (en) * 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
EP2870246B1 (en) 2012-07-03 2019-09-11 BioMarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
AU2013308045B2 (en) * 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
AU2016250576C1 (en) * 2015-04-23 2021-05-06 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
WO2021198958A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Nucleic acid polymers
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
EP4367241A1 (en) 2021-07-09 2024-05-15 GlaxoSmithKline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074041A1 (en) * 1997-08-20 2006-04-06 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US20070105116A1 (en) 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid
JP2009500020A (ja) * 2005-07-01 2009-01-08 バイオヴェリス コーポレイション 核酸を検出、増幅および／また単離するための組成物および方法
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074041A1 (en) * 1997-08-20 2006-04-06 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Biol Inorg Chem. 2007. Vol.12, pp. 901-911.*
Nucleic Acids Symposium Series. 2008. No.52, pp.485-486.*

Also Published As

Publication number Publication date
NZ606364A (en) 2014-12-24
DOP2013000041A (es) 2017-12-15
WO2012021985A1 (en) 2012-02-23
EP2605794A1 (en) 2013-06-26
PL2605794T3 (pl) 2017-01-31
SG187165A1 (en) 2013-02-28
HK1198123A1 (en) 2015-03-13
HUE029521T2 (en) 2017-03-28
CN103768086A (zh) 2014-05-07
CN103768086B (zh) 2015-10-14
AU2011291401A1 (en) 2013-01-10
JP2013536195A (ja) 2013-09-19
CA2806616C (en) 2015-08-11
PH12013500192B1 (en) 2018-11-23
CA2855690C (en) 2015-08-25
US8513211B2 (en) 2013-08-20
IL224237A (en) 2015-09-24
BR112013003875A2 (en) 2018-03-13
MY160961A (en) 2017-03-31
HRP20161333T1 (hr) 2016-12-02
AU2011291401B2 (en) 2014-11-27
US8716259B2 (en) 2014-05-06
CR20130069A (es) 2013-09-20
MX2013001668A (es) 2013-07-22
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
ECSP13012449A (es) 2013-04-30
KR20150039873A (ko) 2015-04-13
PT2605794T (pt) 2016-10-25
RS55245B1 (sr) 2017-02-28
MX340294B (es) 2016-07-04
US20130296410A1 (en) 2013-11-07
US20120046348A1 (en) 2012-02-23
EA201300259A1 (ru) 2013-12-30
CN103052405A (zh) 2013-04-17
HK1184058A1 (zh) 2014-01-17
CO6670525A2 (es) 2013-05-15
KR20150082685A (ko) 2015-07-15
SMT201600370B (it) 2016-11-10
EP2605794B1 (en) 2016-07-20
CA2855690A1 (en) 2012-02-23
EP2605794A4 (en) 2014-07-02
EA026660B1 (ru) 2017-05-31
ZA201300497B (en) 2013-09-25
CU20130022A7 (es) 2013-04-19
DK2605794T3 (en) 2016-10-24
BR112013003875B1 (pt) 2021-10-05
GT201300040A (es) 2014-09-02
CA2806616A1 (en) 2012-02-23
JP5775581B2 (ja) 2015-09-09
PH12013500192A1 (https=) 2013-03-11
CN103052405B (zh) 2015-11-25
LT2605794T (lt) 2016-10-25
KR20130099067A (ko) 2013-09-05
SI2605794T1 (sl) 2017-01-31
CL2013000445A1 (es) 2013-11-22

Similar Documents

Publication Publication Date Title
KR101606495B1 (ko) 올리고뉴클레오타이드 킬레이트 복합체
US9616083B2 (en) Oligonucleotide chelate complex methods
CA2873529C (en) Oligonucleotide chelate complex-polypeptide compositions and methods
HK1198123B (en) The use of oligonucleotide chelate complexes
HK1184058B (en) Oligonucleotide chelate complexes
WO2001034093A2 (en) Potentiation of prodrug efficacy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190307

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240322

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240322